Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression.
Koneczny I, Mané-Damas M, Zong S, De Haas S, Huda S, van Kruining D, Damoiseaux J, De Rosa A, Maestri M, Guida M, Molenaar P, Van Damme P, Fichtenbaum A, Perkmann T, De Baets M, Lazaridis K, Zouvelou V, Tzartos S, Ricciardi R, Losen M, Martinez-Martinez P. Koneczny I, et al. Among authors: lazaridis k. Front Immunol. 2024 Apr 23;15:1325171. doi: 10.3389/fimmu.2024.1325171. eCollection 2024. Front Immunol. 2024. PMID: 38715598 Free PMC article.
Silencing of FCRLB by shRNA ameliorates MuSK-induced EAMG in mice.
Koral G, Ulusoy C, Cossins J, Lazaridis K, Türkoğlu R, Dong YY, Tüzün E, Yılmaz V. Koral G, et al. Among authors: lazaridis k. J Neuroimmunol. 2023 Oct 15;383:578195. doi: 10.1016/j.jneuroim.2023.578195. Epub 2023 Aug 30. J Neuroimmunol. 2023. PMID: 37660538
Ravulizumab and Efgartigimod in Myasthenia Gravis: A Real-World Study.
Stascheit F, Sousa CDF, Aigner A, Behrens M, Keller CW, Klotz L, Lehnerer S, Stein M, Herdick M, Doksani P, Gerischer LM, Hoffmann S, Lazaridis K, Tzartos J, Wiendl H, Meisel A, Lünemann JD. Stascheit F, et al. Among authors: lazaridis k. Neurol Neuroimmunol Neuroinflamm. 2025 Jan;12(1):e200331. doi: 10.1212/NXI.0000000000200331. Epub 2024 Nov 27. Neurol Neuroimmunol Neuroinflamm. 2025. PMID: 39602677 Free PMC article.
Novel Competitive ELISA Utilizing Trimeric Spike Protein of SARS-CoV-2, Could Identify More Than RBD-RBM Specific Neutralizing Antibodies in Hybrid Sera.
Eliadis P, Mais A, Papazisis A, Loxa EK, Dimitriadis A, Sarrigeorgiou I, Backovic M, Agallou M, Zouridakis M, Karagouni E, Lazaridis K, Mamalaki A, Lymberi P. Eliadis P, et al. Among authors: lazaridis k. Vaccines (Basel). 2024 Aug 13;12(8):914. doi: 10.3390/vaccines12080914. Vaccines (Basel). 2024. PMID: 39204038 Free PMC article.
Combined monitoring of IgG and IgA anti-Spike and anti-Receptor binding domain long term responses following BNT162b2 mRNA vaccination in Greek healthcare workers.
Sarrigeorgiou I, Moschandreou D, Dimitriadis A, Tsinti G, Sotiropoulou E, Ntoukaki E, Eliadis P, Backovic M, Labropoulou S, Escriou N, Pouliakis A, Giannopoulou G, Gaitanarou E, Lazaridis K, Mentis A, Mamalaki A, Grouzi E, Lymberi P. Sarrigeorgiou I, et al. Among authors: lazaridis k. PLoS One. 2022 Nov 21;17(11):e0277827. doi: 10.1371/journal.pone.0277827. eCollection 2022. PLoS One. 2022. PMID: 36409702 Free PMC article.
Factors Associated With Enrollment to a Decentralized Study.
Bharucha AE, Bublitz ML, Vierkant RA, Luehrs TC, Konzen KA, Weiss DA, Hart TA, Boos CM, Allen AM, Bailey KR, Lazaridis KN. Bharucha AE, et al. Among authors: lazaridis kn. Mayo Clin Proc. 2024 Dec 5:S0025-6196(24)00163-0. doi: 10.1016/j.mayocp.2024.03.022. Online ahead of print. Mayo Clin Proc. 2024. PMID: 39641710
Mayo Clinic Tapestry Study: A Large-Scale Decentralized Whole Exome Sequencing Study for Clinical Practice, Research Discovery, and Genomic Education.
Bandel LA, Vierkant RA, Kruisselbrink TM, Bublitz ML, Wilson TA, Armasu SM, Egan JB, Presutti RJ, Samadder NJJ, Sekulic A, Olson RJ, Tan-Arroyo J, Morales-Rosado JA, Klee EW, Ferber MJ, Kemppainen JL, Anderson JL, Bidwell JS, Wick JJ, Ortega VE, Bobo WV, Pichurin PN, Mcmillan JM, Weaver DM, Riegert-Johnson DL, Cera AM, Boucher LM, Kullo IJ, Mantia SK, Jones MT, Larson NB, Luehrs TC, Leitzke JW, Sicotte H, Tian S, Stavlund JR, Pacyna JE, Sharp RR, Asabere AA, Lu J, McAllister TM, Walker TS, Stewart AK, Farrugia G, Lazaridis KN. Bandel LA, et al. Among authors: lazaridis kn. Mayo Clin Proc. 2024 Nov 5:S0025-6196(24)00405-1. doi: 10.1016/j.mayocp.2024.08.005. Online ahead of print. Mayo Clin Proc. 2024. PMID: 39625429
Epigenetic disease markers in primary sclerosing cholangitis and primary biliary cholangitis-methylomics of cholestatic liver disease.
Juran BD, McCauley BM, Atkinson EJ, Schlicht EM, Bianchi JK, Vollenweider JM, Ye H, LaRusso NF, Gores GJ, Sun Z, Lazaridis KN. Juran BD, et al. Among authors: lazaridis kn. Hepatol Commun. 2024 Jul 18;8(8):e0496. doi: 10.1097/HC9.0000000000000496. eCollection 2024 Aug 1. Hepatol Commun. 2024. PMID: 39023332 Free PMC article.
Exome Sequencing Identifies Carriers of the Autosomal Dominant Cancer Predisposition Disorders Beyond Current Practice Guideline Recommendations.
Samadder NJ, Gay E, Lindpere V, Bublitz ML, Bandel LA, Armasu SM, Vierkant RA, Ferber MJ, Klee EW, Larson NB, Kruisselbrink TM, Egan JB, Kemppainen JL, Bidwell JS, Anderson JL, McAllister TM, Walker TS, Kunze KL, Golafshar MA, Klint MA, Presutti RJ, Bobo WV, Sekulic A, Summer-Bolster JM, Willman CL, Lazaridis KN. Samadder NJ, et al. Among authors: lazaridis kn. JCO Precis Oncol. 2024 Jul;8:e2400106. doi: 10.1200/PO.24.00106. JCO Precis Oncol. 2024. PMID: 39013133
IL-17 signaling in primary sclerosing cholangitis patient-derived organoids.
Garcia Moreno AS, Guicciardi ME, Wixom AQ, Jessen E, Yang J, Ilyas SI, Bianchi JK, Pinto E Vairo F, Lazaridis KN, Gores GJ. Garcia Moreno AS, et al. Among authors: lazaridis kn. Hepatol Commun. 2024 Jun 3;8(6):e0454. doi: 10.1097/HC9.0000000000000454. eCollection 2024 Jun 1. Hepatol Commun. 2024. PMID: 38829197 Free PMC article.
232 results